<DOC>
	<DOCNO>NCT00160407</DOCNO>
	<brief_summary>The purpose study determine orlistat ( Xenical ) therapy overweight patient NASH lead enhance weight loss time , subsequent improvement underlie necroinflammatory fibrotic change typical NASH .</brief_summary>
	<brief_title>Orlistat ( Xenical ) Treatment Overweight Patients With Nonalcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description>Previous study suggest steady weight loss time result improvement aminotransferase , importantly , underlie histopathology patient NASH . A total 50 biopsy-proven NASH patient enrol prospective , randomized fashion . Twenty-five patient enrol primary study site Saint Louis University . Recruitment next 25 patient take place study subsite Brooke Army Medical Center San Antonio , Texas . This open-label study compare establish weight loss program ( 1400-calorie diet 30 % fat ) plus daily vitamin E ( 800 IU ) daily multivitamin weight loss program , daily vitamin E ( 800 IU ) multivitamin , plus orlistat ( 120 mg ) , three time daily 36 week . Data collect prospective patient include demographic information , age , sex , past medical history , medication , height weight . Biochemical data collect prospective patient include liver enzyme , measure insulin resistance include , insulin level , lipid panel , hemoglobin A1C , free fatty acid , complete blood count , coagulation study , vitamin E level . Blood also collect stored marker inflammation fibrosis , C reactive protein TNF-alpha . A liver biopsy obtain completion study histopathologic analysis RNA analysis .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>Liver biopsy obtain 24 month randomization pathology report confirm histological diagnosis consistent NASH Compensated liver disease follow laboratory parameter entry visit : Hemoglobin value great equal 12 gm/dl female 13 gm/dl male WBC count &gt; 3,000/mm3 Neutrophil count &gt; 1,500/mm3 Platelets &gt; 70,000/mm3 Albumin &gt; 3.0 g/dl Serum creatinine &lt; 1.4mg/dl Ability give inform consent Alanine aminotransferase ( ALT ) great equal 40 U/L BMI &gt; equal 27 kg/m2 Patients receive orlistat must agree participate Xenicare , free dietary counseling program provide Roche ( sponsor ) Any cause chronic liver disease NASH Evidence decompensated liver disease history presence ascites , bleed varix , spontaneous encephalopathy History alcohol consumption great 20 gram per day past 2 year Prior surgical procedure include gastroplasty , jejunoileal jejunocolic bypass TPN within past 6 month History prior organ transplantation Concurrent enrollment experimental treatment protocol Use ursodeoxycholic acid , rosiglitazone , pioglitazone , metformin within 6month period enrollment Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>nonalcoholic steatohepatitis</keyword>
	<keyword>enzyme inhibitor</keyword>
	<keyword>lipase</keyword>
	<keyword>obesity</keyword>
	<keyword>insulin resistance</keyword>
</DOC>